'On consolidated basis
Quarter ended September 2025 compared with Quarter ended September 2024.
Net sales (including other operating income) of Gland Pharma has increased 5.77% to Rs 1486.88 crore. Operating profit margin has declined from 21.13% to 21.11%, leading to 5.66% rise in operating profit to Rs 313.88 crore. Raw material cost as a % of total sales (net of stock adjustments) increased from 36.84% to 37.39%. Purchase of finished goods cost fell from 0.20% to 0.13%. Employee cost increased from 25.01% to 25.78%. Other expenses rose from 15.43% to 15.68%. Power and Oil fuel cost fell from 3.44% to 3.36%.
Other income rose 41.07% to Rs 84.16 crore. PBIDT rose 11.58% to Rs 398.04 crore. Provision for interest rose 27.99% to Rs 7.82 crore. Loan funds declined from Rs 326.63 crore as of 30 September 2024 to Rs 302.25 crore as of 30 Septe...
Pleaselogin & subscribe to view the full report.
More Reports
|
|